Article
Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Feb 2014
Kanwal Fasiha, White Donna L, Tavakoli-Tabasi Shahriar, Jiao Li, Lin Derek, Ramsey David J, Spiegelman Andrew, Kuzniarek Jill, El-Serag Hashem B
Abstract excerpt
BACKGROUND & AIMS: Interleukin (IL)-28B (interferon-λ 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy. However, patients with HCV infection often have physical or mental comorbidities that contraindicate or complicate trea...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.